Search company, investor...

ProDuct

Stage

Other Investors | Alive

About ProDuct

ProDuct Health was founded to develop and commercialize products enabling early detection and treatment of breast cancer. ProDuct was acquired by Cytyc.

Headquarters Location

ArthroCare Corporation 7500 Rialto Boulevard Building Two, Suite 100 Austin, Texas 78735-8532 ArthroCare Corporation 680 Vaqueros Avenue Sunnyvale, CA 94085-3523

78735,

Missing: ProDuct's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ProDuct's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

ProDuct Patents

ProDuct has filed 1 patent.

The 3 most popular patent topics include:

  • Honeycombs (geometry)
  • Electrical engineering
  • Exercise equipment
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/24/2021

11/22/2022

Grant

Application Date

8/24/2021

Grant Date

11/22/2022

Title

Related Topics

Status

Grant

Latest ProDuct News

Molecular Oncology Diagnostics Market - A Global and Regional Analysis: Focus on Product, Technology, Application, Cancer Type, End User, and Region - Analysis and Forecast, 2022-2032

Dec 2, 2022

Regional Analysis: Focus on Product, Technology, Application, Cancer Type, End User, and Region - Analysis and Forecast, 2022-2032" - https://www.reportlinker.com/p06369347/?utm_source=GNW The global molecular oncology diagnostics market was valued at $3,620.6 million in 2021 and is anticipated to reach $12,130.5 million by 2032, witnessing a CAGR of 11.43% during the forecast period 2022-2032. The growth in the global molecular oncology diagnostics market is expected to be driven by the rising prevalence of cancers and increased transformations in biomarker identification. Market Lifecycle Stage Molecular oncology diagnostics play an essential role in the diagnosis and prognosis of different types of cancers and in improving patient outcomes.Over the last decade, cancer treatment and diagnostics has become a major public health concern across the globe. With over 1.5 million instances reported each year, diseases like cancer can have far-reaching implications for individuals as well as a greater influence on the socioeconomic strata. The market for appropriate testing assay kits is expanding rapidly, owing to the increased importance of early diagnosis to minimize further hazards, especially with rates on the rise. The rising global cancer incidence and the growing demand for early detection are expected to drive the growth of the global molecular oncology diagnostics market during the forecast period. This expanded usage of kit and assay, instrument, and software has enabled end customers to describe particular system requirements, prompting suppliers to design more appealing and practical products and molecular diagnostics choices. Impact • The presence of major kit and assay providers of molecular oncology diagnostics has a major impact on the market. For instance, in March 2021, Biocartis NV launched Idylla GeneFusion Assay as a Rapid Lab Workflow Solution for gene fusion testing. This product provides a much faster testing solution for laboratories in comparison to other testing methods, including NGS. • Companies such as Bio-Rad Laboratories, Inc., in August 2022, acquired Curiosity Diagnostics. The company acquired all the outstanding shares of the latter from Scope Fluidics, S.A. for its growth in the medical diagnostic and healthcare markets, for a total consideration of up to $170 million. Similarly, in February 2022, Becton and Dickinson Company (BD) acquired Cytogons to gain exclusive access to advanced assays licensed from the EuroFlow Consortium and strengthen BD’s leadership position in the molecular oncology diagnostics segment. Impact of COVID-19 Cancer screening is crucial for early cancer detection; however, COVID-19 slowed the cancer screening infrastructure greatly.Many cancer organizations have championed the idea of suspending cancer screening services to patients to alter the provision of health care resources. According to the declaration of a national emergency in the U.S. on March 13th, 2020, organizations such as the American Cancer Society advised people to put their cancer screening plans on hold until further notice during the COVID-19 outbreak. Cancer screening services have been severely disrupted because of this proposal, as well as other contextual circumstances (e.g., social exclusion measures). In response to the COVID-19 pandemic and the impact on medical research in the U.S., the National Institutes of Health (NIH) and the National Cancer Institute (NCI) both extended grant application deadlines, laid back reporting requirements, and offer flexibility in how to grant money is spent. COVID-19 drastically reduced fundraising possibilities for cancer-focused charitable research organizations, which provide up to half of all cancer research funding in the U.S. and frequently fund high-risk, high-reward projects even though the national government supported research work and offered medical researchers the flexibility to implement their skill set and knowledge to studying SARSCoV-2. Market Segmentation:

ProDuct Frequently Asked Questions (FAQ)

  • What is ProDuct's latest funding round?

    ProDuct's latest funding round is Other Investors.

  • Who are the investors of ProDuct?

    Investors of ProDuct include Three Arch Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.